Metacrine Posts Data From MET409 Combination Trial In Diabetes, NASH Patients

Metacrine Inc MTCR reported topline results from its Phase 2a trial of MET409 in combination with Eli Lilly And Co's LLY Jardiance (empagliflozin) in type 2 diabetes and non-alcoholic steatohepatitis (NASH).
LDL-cholesterol increases with MET409 were consistent with previous studies and were comparable alone or in combination with empagliflozin.
Secondary assessment of liver fat content at 12 weeks indicated a reduction in liver fat in both monotherapy arms and demonstrated additive effects in the combination regimen.
All regimens had favorable safety profiles and were generally well-tolerated, with no treatment-related serious adverse events (AEs).
Mild-moderate pruritus was reported in 0%-6% of patients across all groups. No pruritus-related treatment discontinuations occurred in any of the cohorts.
Price Action: MTCR shares are up 1.06% at $1.43 during the market session on the last check Tuesday.

Momentum42.22

Growth99.76

Quality93.03

Value3.28

Short

Medium

Long